Macrolides and Ketolides — MCQs
Which of the following is NOT a mechanism of antibiotic resistance?
What is the mechanism of action of aminoglycoside antibiotics?
What is the mechanism of resistance in MRSA?
Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?
Which is the widest spectrum aminoglycoside?
An adult man presents with the clinical condition shown in the image, and a Gram stain reveals Gram-negative diplococci. What is the most appropriate treatment?
Which one of the following antibiotics inhibits transpeptidation in bacterial cell wall synthesis?
Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
Why does Mycoplasma genitalium show a higher rate of antimicrobial resistance compared to other STI pathogens?
A 14-year-old boy presents with headache, fever, and cough for 2 days. Sputum is scant and non-purulent and gram stain reveals many white cells but no organisms. The treatment should be initiated with :
Macrolides and Ketolides Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is NOT a mechanism of antibiotic resistance?
- A. Efflux pump activity
- B. Inactivation by enzymes such as beta-lactamase
- C. Modification of drug target sites
- D. Increased drug absorption (Correct Answer)
Explanation: ***Increased drug absorption*** - **Increased drug absorption** would lead to a higher intracellular concentration of the antibiotic, making it *more potent* against the bacteria rather than contributing to resistance. - Antibiotic resistance mechanisms aim to *reduce the effective concentration* of the drug at its target site or *alter the target itself*. *Efflux pump activity* - **Efflux pumps** are bacterial membrane proteins that actively pump antibiotics out of the bacterial cell [3]. - This mechanism *reduces the intracellular concentration* of the antibiotic, preventing it from reaching its therapeutic target [3]. *Inactivation by enzymes such as beta-lactamase* - Bacteria can produce enzymes like **beta-lactamase** that *chemically modify or degrade* the antibiotic molecule, rendering it inactive [2]. - This is a common mechanism of resistance against **beta-lactam antibiotics** (e.g., penicillin, cephalosporins) [2]. *Modification of drug target sites* - Bacteria can develop mutations that *alter the structure of the antibiotic's target site*, such as a bacterial ribosome or cell wall component [1]. - This change in the target means the antibiotic can no longer bind effectively or interfere with cellular processes, thus *losing its efficacy* [1].
Question 2: What is the mechanism of action of aminoglycoside antibiotics?
- A. Inhibition of protein synthesis (Correct Answer)
- B. Inhibition of DNA replication
- C. Disruption of the cell membrane
- D. Inhibition of bacterial cell wall synthesis
Explanation: ***Inhibition of protein synthesis*** - Aminoglycosides **bind irreversibly to the 30S ribosomal subunit** of bacteria, interfering with the initiation complex formation and causing misreading of mRNA. - This leads to the production of **non-functional proteins** and ultimately bacterial cell death, making them bactericidal. *Disruption of the cell membrane* - This mechanism is characteristic of **polymyxins** (e.g., colistin), which interact with bacterial cell membranes, increasing permeability and causing leakage of intracellular contents. - Aminoglycosides do not primarily target the cell membrane for their bactericidal action. *Inhibition of DNA replication* - This mechanism is associated with **fluoroquinolones**, which inhibit bacterial topoisomerase II (DNA gyrase) and topoisomerase IV. - Aminoglycosides do not interfere with DNA synthesis or replication. *Inhibition of bacterial cell wall synthesis* - This is the mechanism of action for **beta-lactam antibiotics** (e.g., penicillins, cephalosporins) and **glycopeptides** (e.g., vancomycin), which target peptidoglycan synthesis. - Aminoglycosides do not affect the bacterial cell wall but rather their intracellular protein machinery.
Question 3: What is the mechanism of resistance in MRSA?
- A. PBP2a alteration (Correct Answer)
- B. Efflux pump activation
- C. Porins modification
- D. Beta-lactamase production
Explanation: ***PBP2a alteration*** - Methicillin-resistant Staphylococcus aureus (MRSA) acquires the **mecA gene**, which encodes for a modified penicillin-binding protein, **PBP2a**. - **PBP2a** has a low affinity for **beta-lactam antibiotics**, allowing the bacteria to synthesize its cell wall even in the presence of these drugs. *Efflux pump activation* - Efflux pumps are mechanisms used by bacteria to actively pump out various antibiotics from their cells, leading to resistance. - While efflux pumps contribute to resistance against other antibiotics, they are **not the primary mechanism** of methicillin resistance in MRSA. *Porins modification* - Porins are channels in the outer membrane of Gram-negative bacteria that allow the passage of hydrophilic molecules, including some antibiotics. - Modification of porins is a common resistance mechanism in **Gram-negative bacteria** but is not relevant to MRSA, which is Gram-positive. *Beta-lactamase production* - Beta-lactamases are enzymes that **hydrolyze the beta-lactam ring** of antibiotics like penicillin, rendering them inactive. - While many Staphylococcus aureus strains produce beta-lactamase (penicillinase) causing resistance to penicillins, MRSA's resistance to methicillin and other broader-spectrum beta-lactams is primarily due to **PBP2a alteration**, not just beta-lactamase production.
Question 4: Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?
- A. Amoxicillin
- B. Cefotaxime
- C. Erythromycin (Correct Answer)
- D. Cotrimoxazole
Explanation: ***Erythromycin*** - **Erythromycin**, a macrolide antibiotic, is a potent inhibitor of the **cytochrome P450 (CYP450) enzyme system**, specifically **CYP1A2**, which is the primary enzyme responsible for theophylline metabolism. - Co-administration of erythromycin can significantly **increase theophylline levels**, leading to toxicity such as **nausea, vomiting, seizures, or cardiac arrhythmias.** - This interaction is clinically significant and erythromycin should be avoided in patients on theophylline therapy. *Amoxicillin* - **Amoxicillin** is a penicillin-class antibiotic that has minimal interaction with theophylline metabolism. - It does not significantly inhibit the **CYP1A2 enzyme** and is generally considered safe to use with theophylline. *Cefotaxime* - **Cefotaxime**, a third-generation cephalosporin, does not significantly affect the metabolism of theophylline. - It does not inhibit **CYP1A2 enzymes** and is safe for use in patients on theophylline therapy. *Cotrimoxazole* - **Cotrimoxazole** (trimethoprim/sulfamethoxazole) may slightly increase theophylline levels by inhibiting some CYP450 isoenzymes, but its effect is generally less pronounced than that of erythromycin. - While caution and monitoring are advised, it is not as strongly contraindicated as erythromycin due to a lower risk of significant toxicity in most cases.
Question 5: Which is the widest spectrum aminoglycoside?
- A. Streptomycin
- B. Amikacin (Correct Answer)
- C. Framycetin
- D. Netilmicin
Explanation: ***Amikacin*** - **Amikacin** has the **widest spectrum** among aminoglycosides, showing activity against many gram-negative bacteria, including those resistant to other aminoglycosides. - Its chemical structure offers increased resistance to many **aminoglycoside-modifying enzymes**, broadening its utility against difficult-to-treat infections. *Streptomycin* - **Streptomycin** is primarily used for **tuberculosis** and certain other specific infections like plague and tularemia. - It has a much **narrower spectrum** compared to amikacin, with limited activity against many common gram-negative pathogens. *Framycetin* - **Framycetin** is mainly used as a **topical antibiotic** for skin, eye, and ear infections. - It has a **limited systemic use** due to its toxicity and spectrum, which is not as broad as amikacin. *Netilmicin* - **Netilmicin** offers activity against some gram-negative bacteria, including those resistant to gentamicin and tobramycin. - While it has a good spectrum, it is **not as broad** as amikacin, especially concerning strains with multiple resistance mechanisms.
Question 6: An adult man presents with the clinical condition shown in the image, and a Gram stain reveals Gram-negative diplococci. What is the most appropriate treatment?
- A. Ceftriaxone (Correct Answer)
- B. Azithromycin
- C. Doxycycline
- D. Acyclovir
Explanation: ***Ceftriaxone*** - The image shows **urethritis** (discharge from the urethra), and the Gram stain revealing **Gram-negative diplococci** is characteristic of **Neisseria gonorrhoeae**. - **Ceftriaxone** is the recommended first-line treatment for **gonorrhea**, often administered as a single intramuscular dose. *Azithromycin* - While often co-administered with ceftriaxone to cover potential **Chlamydia coinfection**, it is not the primary treatment for gonorrhea alone. - Azithromycin is the main treatment for uncomplicated **Chlamydia trachomatis** infections. *Doxycycline* - **Doxycycline** is a highly effective antibiotic for treating **Chlamydia trachomatis** infections and certain other bacterial STIs. - It is not the primary treatment for **gonorrhea** due to resistance concerns and preferred efficacy of cephalosporins. *Acyclovir* - **Acyclovir** is an antiviral medication used to treat infections caused by the **herpes simplex virus (HSV)**. - It has no activity against **bacterial infections** like gonorrhea, making it inappropriate for this presentation.
Question 7: Which one of the following antibiotics inhibits transpeptidation in bacterial cell wall synthesis?
- A. Penicillin (Correct Answer)
- B. Chloramphenicol
- C. Amphotericin
- D. Vancomycin
Explanation: ***Penicillin*** - Penicillin is a **beta-lactam antibiotic** that targets bacterial cell wall synthesis by inhibiting the enzyme **transpeptidase** (penicillin-binding proteins). - This inhibition prevents the cross-linking of **peptidoglycan strands**, leading to a weakened cell wall and subsequent bacterial lysis. *Chloramphenicol* - **Chloramphenicol** inhibits bacterial protein synthesis by binding to the **50S ribosomal subunit**, thereby preventing peptide bond formation (peptidyl transferase activity). - It does not act on the bacterial cell wall. *Vancomycin* - **Vancomycin** is a **glycopeptide antibiotic** that inhibits bacterial cell wall synthesis by binding to the **D-Ala-D-Ala terminus** of peptidoglycan precursors. - It prevents the **transglycosylation and transpeptidation steps** by blocking substrate access, but it does not directly inhibit the transpeptidase enzyme itself like beta-lactams do. - Its mechanism is distinct from penicillin's direct enzyme inhibition. *Amphotericin* - **Amphotericin B** is an **antifungal agent** that targets the fungal cell membrane by binding to **ergosterol**, forming pores that disrupt membrane integrity. - It has no activity against bacterial cell wall synthesis.
Question 8: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Explanation: ***Atorvastatin + Itraconazole*** - **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism. - Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**. *Amiodarone + Atorvastatin* - **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole. - While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole. - The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole. *Carbamazepine + Atorvastatin* - **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition. - This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity. *Phenytoin + Atorvastatin* - **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine. - Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Question 9: Why does Mycoplasma genitalium show a higher rate of antimicrobial resistance compared to other STI pathogens?
- A. Due to plasmid exchange with other bacteria
- B. Due to absence of cell wall making beta-lactams ineffective
- C. Due to biofilm formation protecting from antibiotics
- D. Due to rapid mutation in the 23S rRNA gene (Correct Answer)
Explanation: ***Due to rapid mutation in the 23S rRNA gene*** [1] - *Mycoplasma genitalium* develops **resistance to macrolides**, a primary treatment, through **point mutations in the 23S rRNA gene** [1]. - These mutations alter the ribosomal binding site, preventing macrolide antibiotics from inhibiting **bacterial protein synthesis** [2]. *Due to plasmid exchange with other bacteria* - *Mycoplasma genitalium* **lacks a cell wall** and generally does not engage in significant plasmid exchange, which is a common mechanism for horizontal gene transfer and resistance acquisition in many other bacteria. - While other bacteria acquire resistance through plasmids, this mechanism is **not prominent** in *Mycoplasma genitalium*. *Due to absence of cell wall making beta-lactams ineffective* - The **absence of a cell wall** inherently makes beta-lactam antibiotics ineffective against *Mycoplasma genitalium*, as **beta-lactams target cell wall synthesis**. - However, this is a **natural resistance** and does not explain its higher rate of acquired antimicrobial resistance to other classes of antibiotics, such as macrolides. *Due to biofilm formation protecting from antibiotics* - While **biofilm formation can protect bacteria** from antibiotics, it is not the primary or most notable mechanism explaining the high rate of acquired resistance in *Mycoplasma genitalium*. - The major concern for *M. genitalium* resistance lies in **specific genetic mutations** affecting relevant antibiotic targets.
Question 10: A 14-year-old boy presents with headache, fever, and cough for 2 days. Sputum is scant and non-purulent and gram stain reveals many white cells but no organisms. The treatment should be initiated with :
- A. Azithromycin (Correct Answer)
- B. Levofloxacin
- C. Amikacin
- D. Cefazolin
Explanation: ***Azithromycin*** - The clinical picture of **headache, fever, cough, scant non-purulent sputum**, and Gram stain showing white cells but no organisms is highly suggestive of **atypical pneumonia**, likely caused by *Mycoplasma pneumoniae* in this age group. - **Macrolides** like azithromycin are the **first-line treatment** for atypical pneumonia as they are effective against organisms like *Mycoplasma* and *Chlamydia* which lack cell walls and are therefore resistant to beta-lactam antibiotics. *Levofloxacin* - **Levofloxacin** is a **fluoroquinolone**, which is effective against atypical pathogens but is generally reserved for **older patients** or those with **allergies** to macrolides due to concerns about potential side effects like cartilage damage in children. - Using fluoroquinolones as a first-line treatment in adolescents for suspected atypical pneumonia is **not recommended** due to these potential side effects and the availability of safer alternatives. *Amikacin* - **Amikacin** is an **aminoglycoside antibiotic** primarily used for severe infections caused by **Gram-negative bacteria**. - It is **ineffective against atypical bacteria** like *Mycoplasma* or *Chlamydia* which are the likely causative agents in this scenario. *Cefazolin* - **Cefazolin** is a **first-generation cephalosporin**, which is a **beta-lactam antibiotic** effective mostly against Gram-positive cocci and some Gram-negative bacteria. - It is **ineffective against atypical pathogens** because these organisms **lack a cell wall** (like *Mycoplasma*) or have cell walls that are not targeted by beta-lactam antibiotics.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free